FindTrial
Sign In

Phase 2/3 clinical study of HP-3150 in patients with cancer pain.

Phase 2/3 clinical study of HP-3150 in patients with cancer pain.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222905
Enrollment
Unknown
Registered
2015-07-06
Start date
2015-07-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer pain

Interventions

investigational material(s) Generic name etc : HP-3150 INN of investigational material : Therapeutic category code : 264 Analgesics, anti-itchings, astrigents and anti-inflammatory agents Dosage and

Sponsors

Hisamitsu Pharmaceutical Co., Inc
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients confirmed to have various types of cancer who were informed about their disease.

Exclusion criteria

Exclusion criteria: - Patients with abnormalities at the planned application site. - Patients with a serious hematologic disorder, hepatic dysfunction, renal dysfunction, hypertension, or heart failure. - Patients who have undergone an operation or nerve block, etc. that may affect assessment of pain.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026